FI104490B - Förfarande för framställning av terapeutiskt användbara sulfatiserade polysackaridblandningar - Google Patents

Förfarande för framställning av terapeutiskt användbara sulfatiserade polysackaridblandningar Download PDF

Info

Publication number
FI104490B
FI104490B FI913101A FI913101A FI104490B FI 104490 B FI104490 B FI 104490B FI 913101 A FI913101 A FI 913101A FI 913101 A FI913101 A FI 913101A FI 104490 B FI104490 B FI 104490B
Authority
FI
Finland
Prior art keywords
heparin
ester
process according
molecular weight
chains
Prior art date
Application number
FI913101A
Other languages
English (en)
Finnish (fi)
Other versions
FI913101A (fi
FI913101A0 (fi
Inventor
Roger Debrie
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9398013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI104490(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI913101A0 publication Critical patent/FI913101A0/fi
Publication of FI913101A publication Critical patent/FI913101A/fi
Application granted granted Critical
Publication of FI104490B publication Critical patent/FI104490B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (12)

1. Förfarande för framstalining av terapeutiskt an-vändbara sulfatiserade polysackaridblandningar, vilka har 5 den allmänna strukturen för polysackarider sora föreligger som strukturdelar i heparin och vars medelmolmassa är min-dre an heparin, 9 - 20 % av kedjorna har en molmassa min-dre In 2000 Dalton och 5 - 20 % av kedjorna har en molmassa over 8000 Dalton, och vilkas förhällande mellan viktme-10 delmolmassa och talmedelmolmassa lr 1,3 - 1,6, känne- t e c k n a t därav, att i det första steget saltas heparin in i en vatten-lösning med hjälp av ett längkedjat kvaternärt ammonium-salt , 15. det andra steget esterifieras det sä erhällna sal- tet för bilda en ester, som har en esterifieringsgrad av 9,5 % - 14 %, och i det tredje steget depolymeriseras den erhällna estern, som har en esterifieringsgrad av 9,5 % - 14 %. 20
2. Förfarande för framställning av en blandning en- ligt patentkravet 1, som innehäller under 2 % dermatansul-f at.
, 3. Förfarande för framställning av en blandning en- ' <11 ligt patentkravet 1, vars medelmolmassa är cirka 3500 -···' 25 5500 Daltonia. • 1
4. Förfarande för framställning av en blandning en- • · 1 • 1.· ligt patentkravet 1, som i den andra ändan av de sulfa- *!"! tiserade polysackaridkedjorna har en 2-O-sulfo-4-enopy- ranosiuronsyra. 30
5. Förfarande enligt patentkravet 1, k ä n n e - t e c k n a t därav, att det andra steget utförs i klore- • « « rad organisk lösningsmedel med klorderivat. • · ·
6. Förfarande enligt patentkravet 5, k ä n n e - * 1 t e c k n a t därav, att klorderivatet är benzylklorid 35 och lösningsmedlet är kloroform eller metylenklorid. • · · • · · ♦ 104490
7. Förfarande enligt nägot patentkrav 1, 5 eller 6, kännetecknat därav, att esterifieringen utförs genom att 1 viktdel av heparins salt blandas med cirka 1 volymdel klorderivat i 3 - 5 volymdelen klorerat organiskt 5 lösningsmedel vid en temperatur av 25 - 40 °C och företrä- desvis vid 30 - 40 °C.
8. Förfarande enligt patentkravet 1, kännetecknat därav, att det tredje steget utförs genom att estern bearbetas med en stark bas i en vattenlösning. 10
9. Förfarande enligt patentkravet 8, känne tecknat därav, att viktförhällandet bas/ester är 0,05 - 0,2 och företrädesvis 0,08 - 0,15.
10. Förfarande enligt patentkravet 8, kännetecknat därav, att viktförhällandet vatten/ester är 15 15 - 30.
11. Förfarande enligt patentkravet 8, kännetecknat därav, att lösningens temperatur regleras tili 50 - 70 °C och företrädesvis tili 55 - 65 °C, och reaktionen utförs frän 30 minuter till 3 timmar och före- 20 trädesvis 1-2 timmar.
12. Förfarande enligt nägot patentkrav 1-11, kännetecknat därav, att det i det första ste- . get använda rämaterialet heparin har behandlas genom ut- • « ... fällning med alkohol. • · • · · • · · « * • · ·· · • · # • · • · IM«I • · • · · • · · • · P • · · • · · I « I • · · • · · • · · « « « « » • « · • * · • * i « · • « ·
FI913101A 1990-06-26 1991-06-25 Förfarande för framställning av terapeutiskt användbara sulfatiserade polysackaridblandningar FI104490B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9008013A FR2663639B1 (fr) 1990-06-26 1990-06-26 Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
FR9008013 1990-06-26

Publications (3)

Publication Number Publication Date
FI913101A0 FI913101A0 (fi) 1991-06-25
FI913101A FI913101A (fi) 1991-12-27
FI104490B true FI104490B (sv) 2000-02-15

Family

ID=9398013

Family Applications (1)

Application Number Title Priority Date Filing Date
FI913101A FI104490B (sv) 1990-06-26 1991-06-25 Förfarande för framställning av terapeutiskt användbara sulfatiserade polysackaridblandningar

Country Status (26)

Country Link
US (1) US5389618A (sv)
JP (1) JP3287363B2 (sv)
KR (1) KR0185586B1 (sv)
AT (1) AT398976B (sv)
AU (1) AU643531B2 (sv)
BE (1) BE1006827A3 (sv)
CA (1) CA2045433C (sv)
CH (1) CH682236A5 (sv)
DK (1) DK176524B1 (sv)
ES (1) ES2036922B9 (sv)
FI (1) FI104490B (sv)
FR (1) FR2663639B1 (sv)
GB (1) GB2245898B (sv)
GR (1) GR1000763B (sv)
HU (1) HU210925B (sv)
IE (1) IE66341B1 (sv)
IL (1) IL98604A (sv)
IT (1) IT1248557B (sv)
LU (1) LU87957A1 (sv)
MX (1) MX25829A (sv)
NL (1) NL194947C (sv)
NO (1) NO304991B1 (sv)
NZ (1) NZ238691A (sv)
PT (1) PT98102B (sv)
SE (1) SE506267C2 (sv)
ZA (1) ZA914869B (sv)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38743E1 (en) 1990-06-26 2005-06-14 Aventis Pharma S.A. Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
US5707973A (en) * 1991-04-23 1998-01-13 Rhone-Poulenc Rorer S.A. Sulfated polysaccharids for treatment or prevention of thromboses
US5849721A (en) * 1992-02-07 1998-12-15 Rhone-Poulenc Rorer S.A. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
FR2687158B1 (fr) * 1992-02-07 1995-06-30 Rhone Poulenc Rorer Sa Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation.
SG67928A1 (en) * 1993-09-30 1999-10-19 Seikagaku Kogyo Co Ltd Antithrombotic
JP4824170B2 (ja) 1999-04-23 2011-11-30 マサチューセッツ インスティテュート オブ テクノロジー ポリマーを表記するためのシステムおよび方法
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
WO2001034114A1 (en) * 1999-11-12 2001-05-17 Emisphere Technologies, Inc. Liquid heparin formulation
US6608042B2 (en) 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
US6969705B2 (en) 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
BR0113886A (pt) * 2000-09-08 2003-07-15 Hamilton Civic Hospitals Res Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
DE50105650D1 (de) 2000-12-16 2005-04-21 Aventis Pharma Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
JP2005505537A (ja) * 2001-08-28 2005-02-24 レオ・ファーマ・アクティーゼルスカブ 低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
JP4828795B2 (ja) * 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
EP1375524B1 (en) * 2002-06-20 2007-03-07 CHEMI S.p.A. Process for the preparation of esters of heparin
US20030236221A1 (en) * 2002-06-20 2003-12-25 Chemi Spa Process for the preparation of esters of heparin
US20040265943A1 (en) * 2002-09-23 2004-12-30 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
FR2844808B1 (fr) * 2002-09-23 2005-02-25 Aventis Pharma Sa Methode de determination de groupements specifiques constituant les heparines ou les heparines de bas poids moleculaire
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
WO2004066808A2 (en) * 2002-12-20 2004-08-12 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
KR20060052692A (ko) * 2003-06-05 2006-05-19 센텔리옹 에스아에스 고콜레스테롤혈증 또는 당뇨병과 관련된 혈관형성 결함을치료하기 위한 섬유모세포 성장 인자를 코딩하는플라스미드
US7956046B2 (en) 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
ITMI20031679A1 (it) * 2003-08-29 2005-02-28 Opocrin Spa Processo per la produzione di eparine a basso peso
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
EP1582531A1 (en) * 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
GB0509433D0 (en) * 2005-05-09 2005-06-15 Uni For Milj Og Biovitenskap Method
ATE552004T1 (de) 2005-11-30 2012-04-15 Istituto G Ronzoni Oral verabreichbare heparinderivate
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
CN100436483C (zh) * 2006-05-24 2008-11-26 杭州九源基因工程有限公司 一种依诺肝素钠的纯化生产方法
AU2007267561B2 (en) 2006-05-25 2012-05-17 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
FR2912409B1 (fr) * 2007-02-14 2012-08-24 Sanofi Aventis Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
AU2009250803A1 (en) * 2008-05-20 2009-11-26 Crystal Clear Partnership Separation of polysaccharides by charge density gradient
EP2233145A1 (en) 2009-03-19 2010-09-29 Sanofi-Aventis A dose of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment
EP2526122B1 (en) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102792158B (zh) 2011-01-28 2013-07-10 杭州九源基因工程有限公司 一种基于毛细管电泳的依诺肝素钠精细结构测定方法
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
AR085961A1 (es) 2011-04-11 2013-11-06 Sanofi Sa Polisacaridos que poseen dos sitios de union a la antitrombina iii, metodo para prepararlos y composiciones farmaceuticas que los contienen
CN102603925B (zh) * 2012-03-21 2013-12-11 东营天东制药有限公司 一种由粗品肝素钠直接生产依诺肝素钠的方法
CN102603926B (zh) * 2012-03-27 2014-04-30 烟台东诚生化股份有限公司 一种高效价肝素钠制备新工艺
CN102633908A (zh) * 2012-05-02 2012-08-15 雷晓刚 一种高品质超低分子量肝素的制备方法
RU2512768C1 (ru) * 2012-12-18 2014-04-10 Федеральное бюджетное учреждение "Государственный институт кровезаменителей и медицинских препаратов (ФБУ "ГИКиМП") Способ получения низкомолекулярного гепарина
CN103145868B (zh) * 2013-01-07 2015-09-16 中国科学院昆明植物研究所 一种低分子量糖胺聚糖衍生物及其药物组合物和其制备方法与应用
CN103175925B (zh) * 2013-03-20 2014-12-03 山东辰中生物制药有限公司 依诺肝素钠生产过程中肝素苄基酯的酯化率的检测方法
CN103214591B (zh) * 2013-04-12 2015-11-04 中国科学院昆明植物研究所 一种含末端2,5-脱水塔罗糖或其衍生物的低分子量糖胺聚糖衍生物
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
US10668015B2 (en) 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
CN109666086B (zh) * 2018-11-05 2020-12-22 上海宝维医药技术有限公司 一种高纯度肝素季铵盐的制备方法及其应用
EP3997238A1 (en) 2019-07-09 2022-05-18 Optimvia, LLC Methods for synthesizing anticoagulant polysaccharides
EP4182452A4 (en) 2020-07-14 2024-07-31 Optimvia Llc METHOD FOR THE SYNTHESIS OF NON-ANTICOAGULATING HEPARAN SULFATE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK108622C (da) * 1963-01-18 1968-01-15 Roussel Uclaf Fremgangsmåde til fremstilling af benzylheparinat eller dets alkalimetalsalte.
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
ATE15142T1 (de) * 1981-05-21 1985-09-15 Akzo Nv Antithrombotikum auf basis von polysacchariden, verfahren zur dessen herstellung und medizinale zusammensetzungen.
FR2548672A1 (fr) * 1983-07-04 1985-01-11 Pharmuka Lab Oligosaccharides sulfates et leur utilisation comme medicaments
DK196886D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
ES2006891A6 (es) * 1988-04-09 1989-05-16 Bioiberica Procedimiento de preparacion de fracciones de oligosacaridos por depolimerizacion quimica controlada de heparina.
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
US5011919A (en) * 1989-01-30 1991-04-30 Ajorca S.A. Modified heparins and obtention process
IT1243300B (it) * 1990-12-20 1994-05-26 Fidia Spa Derivati dell'eparina

Also Published As

Publication number Publication date
GB2245898A (en) 1992-01-15
FR2663639B1 (fr) 1994-03-18
US5389618A (en) 1995-02-14
CH682236A5 (sv) 1993-08-13
FR2663639A1 (fr) 1991-12-27
DK124391D0 (da) 1991-06-25
FI913101A (fi) 1991-12-27
IL98604A0 (en) 1992-07-15
GB2245898B (en) 1993-10-06
PT98102B (pt) 1998-11-30
NZ238691A (en) 1992-07-28
AT398976B (de) 1995-02-27
SE9101957L (sv) 1991-12-27
NO912485D0 (no) 1991-06-25
ZA914869B (en) 1992-04-29
ES2036922A1 (es) 1993-06-01
IT1248557B (it) 1995-01-19
AU643531B2 (en) 1993-11-18
LU87957A1 (fr) 1993-01-15
CA2045433C (fr) 2002-07-30
GB9113589D0 (en) 1991-08-14
ATA128191A (de) 1994-07-15
GR1000763B (el) 1992-12-30
KR0185586B1 (ko) 1999-04-01
BE1006827A3 (fr) 1995-01-03
NL194947B (nl) 2003-04-01
NL194947C (nl) 2003-08-04
PT98102A (pt) 1992-03-31
KR920000792A (ko) 1992-01-29
SE9101957D0 (sv) 1991-06-25
IE912216A1 (en) 1992-01-01
ES2036922B1 (es) 1994-03-01
ITMI911757A1 (it) 1992-12-26
HU210925B (en) 1995-09-28
ES2036922B9 (es) 2012-07-30
HUT57796A (en) 1991-12-30
ITMI911757A0 (it) 1991-06-26
JPH04226101A (ja) 1992-08-14
DK176524B1 (da) 2008-07-14
IL98604A (en) 1998-08-15
FI913101A0 (fi) 1991-06-25
AU7928891A (en) 1992-01-02
NO912485L (no) 1991-12-27
NO304991B1 (no) 1999-03-15
IE66341B1 (en) 1995-12-27
DK124391A (da) 1991-12-27
MX25829A (es) 1993-10-01
SE506267C2 (sv) 1997-11-24
JP3287363B2 (ja) 2002-06-04
CA2045433A1 (fr) 1991-12-27
GR910100270A (en) 1992-08-25
NL9101049A (nl) 1992-01-16

Similar Documents

Publication Publication Date Title
FI104490B (sv) Förfarande för framställning av terapeutiskt användbara sulfatiserade polysackaridblandningar
Wu et al. Anticoagulant and antithrombotic evaluation of native fucosylated chondroitin sulfates and their derivatives as selective inhibitors of intrinsic factor Xase
USRE38743E1 (en) Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
FI88046C (sv) Förfarande för framställning av hepariner med låg molekylvikt
US8609632B2 (en) Low molecular weight heparin composition and uses thereof
US5010063A (en) Heparin derivatives and process for their preparation
US5696100A (en) Method for controlling O-desulfation of heparin and compositions produced thereby
KR840001753B1 (ko) 황산화다당류의 신규 혼합물 제조방법
US5922690A (en) Dermatan disulfate, an inhibitor of thrombin generation and activation
AU2005224415B2 (en) Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same
EP2794665B1 (en) Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
WO1996006867A9 (en) Method for controlling o-desulfation of heparin and compositions produced thereby
US6150342A (en) Heparin derivatives for treatment of angina pectoris
CA2377734A1 (en) Heparin compositions that inhibit clot associated coagulation factors
US20120322760A1 (en) Methods of treatment with a low molecular weight heparin composition
US5849721A (en) Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
AU671817B2 (en) Sulphated polysaccharides, preparation thereof, pharmaceutical composition and use thereof
JP4051099B2 (ja) 低分子化ヘパリン、その製造法及び医薬組成物
EP2427500B1 (en) Novel acylated 1,6-anhydro decasaccharide and its use as antithrombotic agent

Legal Events

Date Code Title Description
MA Patent expired